82 search results for: mechanism of disease

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Dermatology
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
View more
Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
View more
Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in AD
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Type 2 Inflammation
Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.
View more
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
View more
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
View more
Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

Dermatology
Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.
View more
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
expert video

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

Dermatology
Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
View more
Treatment Goals, Current and Emerging Therapies in CSU
expert video

Treatment Goals, Current and Emerging Therapies in CSU

Dermatology
Drs. Maurer and Ensina delve into their thoughts on the latest treatment goals and emerging therapies for CSU in this illuminating interview.
View more
ADVENT On Air - Dermatology
Podcast

ADVENT On Air | Expert Discussions in Dermatology

Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

View more
CRSwNP Triathlon: An Interactive Learning Experience
interactivity

CRSwNP Triathlon: An Interactive Learning Experience

Rhinology
Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
The Impact <b>of</b> Skin Fibrosis in Patients with Prurigo Nodularis
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Dermatology
An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PanamaChange country/region